Amifostine in Treating Patients With Stage II or Stage III Non-small Cell Lung Cancer
NCT00003313
Completed
RATIONALE: Amifostine may be an effective treatment for the toxic side effects caused by radiation therapy and chemotherapy. It is not yet known whether chemotherapy and radiation therapy are more effective with or without amifostine for non-small cell lung cancer. PURPOSE: Randomized phase III trial to determine the effectiveness of amifostine in treating patients who have stage II or stage III non-small cell lung cancer that cannot be surgically removed and who are undergoing chemotherapy and... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/19/2014
Locations: Providence Alaska Medical Center, Anchorage, Alaska
Conditions: Drug/Agent Toxicity by Tissue/Organ, Lung Cancer, Oral Complications, Radiation Toxicity
Register for Updates
S0219, Combination Chemotherapy Followed By Observation or Surgery in Patients With Stage II or Stage III Cancer of the Urothelium
NCT00045630
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells and decrease the need for surgery. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy followed by observation or surgery to remove the bladder (cystectomy) in treating patients who have stage II or stage III cancer of the urothelium.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/16/2013
Locations: Cancer Center at Providence Alaska Medical Center, Anchorage, Alaska
Conditions: Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter, Urethral Cancer
Register for Updates
S0342: Paclitaxel, Carboplatin, and Cetuximab in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
NCT00085501
Completed
RATIONALE: Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop tumor cells from dividing so they stop growing or die. Monoclonal antibodies such as cetuximab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Combining more than one chemotherapy drug with a monoclonal antibody may kill more tumor cells. It is not yet known whether cetuximab is more effective when given at the same time a... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/30/2012
Locations: Alaska Regional Hospital, Anchorage, Alaska
Conditions: Lung Cancer
Register for Updates
Study of Pemetrexed and Carboplatin Compared With Etoposide Carboplatin to Treat Extensive-Stage Small Cell Lung Cancer
NCT00363415
Completed
This study is a Phase 3, global, multi-center, open-label study of patients with extensive-stage small cell lung cancer. Eligible patients will be randomly assigned to receive either pemetrexed plus carboplatin or etoposide plus carboplatin. It is anticipated that pemetrexed plus carboplatin will offer similar survival benefits as compared to etoposide plus carboplatin.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/20/2009
Locations: For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Anchorage, Alaska
Conditions: Small Cell Lung Cancer
Register for Updates